[go: up one dir, main page]

AR039744A1 - Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada - Google Patents

Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada

Info

Publication number
AR039744A1
AR039744A1 ARP030102278A ARP030102278A AR039744A1 AR 039744 A1 AR039744 A1 AR 039744A1 AR P030102278 A ARP030102278 A AR P030102278A AR P030102278 A ARP030102278 A AR P030102278A AR 039744 A1 AR039744 A1 AR 039744A1
Authority
AR
Argentina
Prior art keywords
solubility
dosage forms
pharmacos
compositions
methods
Prior art date
Application number
ARP030102278A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR039744A1 publication Critical patent/AR039744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas de dosificación y dispositivos para mejorar la administración controlada de agentes farmacéuticos por medio del uso de una composición de núcleo farmacéutico que aumenta la solubilidad del agente farmacéutico. Presenta un medio para administrar altas dosis de un fármaco poco soluble en sistemas de dosificación oral de fármacos que son convenientes de tragar para la administración una vez al día. Reivindicación 1: Una composición terapéutica de liberación controlada que comprende un agente terapéutico de baja solubilidad, un vehículo constituido por un polímero estructural y un tensioactivo solubilizante.
ARP030102278A 2002-06-26 2003-06-25 Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada AR039744A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39212802P 2002-06-26 2002-06-26

Publications (1)

Publication Number Publication Date
AR039744A1 true AR039744A1 (es) 2005-03-09

Family

ID=30000814

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030102278A AR039744A1 (es) 2002-06-26 2003-06-25 Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada

Country Status (9)

Country Link
US (1) US20040091529A1 (es)
EP (1) EP1517671A2 (es)
CN (1) CN1678290A (es)
AR (1) AR039744A1 (es)
AU (1) AU2003280087A1 (es)
CA (1) CA2489688A1 (es)
PE (1) PE20040103A1 (es)
TW (1) TW200500098A (es)
WO (1) WO2004002447A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
EP2957281A1 (en) 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
DK1325740T3 (da) * 2001-12-12 2004-08-16 Chemistry & Health Int Bv Stabile granulater indeholdende s-adenosylmethionin og fremgangsmåde til fremstilling deraf
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DE60324332D1 (de) 2002-12-03 2008-12-04 Objet Geometries Ltd Verfahren und vorrichtung für dreidimensionales drucken
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
PL1635792T3 (pl) * 2003-06-26 2009-08-31 Teva Pharmaceutical Industries Ltd Stabilne kompozycje farmaceutyczne pochodnych kwasu 2-aza-bicyklo[3.3.0]-oktano-3-karboksylowego
US7485319B2 (en) * 2003-07-25 2009-02-03 Warner Chilcott Company, Inc. Doxycycline metal complex in a solid dosage form
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US7611728B2 (en) 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
US20070122471A1 (en) * 2003-12-25 2007-05-31 Takeda Pharmaceutical Company Limited Method of improving suitability for granulation
CA2551825A1 (en) * 2003-12-29 2005-07-21 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
AU2004312084A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
JP2007517061A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 新規薬剤組成物及び投与形態物
JP2008506788A (ja) * 2004-05-21 2008-03-06 アルザ・コーポレーシヨン 多剤形態の送達用の薬用量形態
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
CN1320887C (zh) * 2004-09-28 2007-06-13 马晶 一种甲氨蝶呤口腔崩解片及其制备方法
JP2008518669A (ja) * 2004-10-29 2008-06-05 スミス アンド ネフュー インコーポレーテッド 生体吸収性ポリマー
ES2588584T3 (es) * 2005-01-21 2016-11-03 Warner Chilcott Company, Llc Un complejo metálico de tetraciclina en una forma de dosificación sólida
US20070104778A1 (en) * 2005-11-07 2007-05-10 Hongxia Zeng Controlled-release emulsion compositions
US20070231390A1 (en) * 2006-03-29 2007-10-04 Andrx Labs, Llc Formulations including hygroscopic compounds
CA2647705A1 (en) * 2006-04-19 2007-10-25 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
GB2443738A (en) * 2006-11-09 2008-05-14 Proprius Pharmaceuticals Inc A sustained release methotrexate composition and methods of use thereof
EP2394643B1 (en) 2006-11-17 2015-09-02 Supernus Pharmaceuticals, Inc. Sustained-release formulations of topiramate
US20080131501A1 (en) * 2006-12-04 2008-06-05 Supernus Pharmaceuticals, Inc. Enhanced immediate release formulations of topiramate
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
WO2010089132A1 (en) 2009-02-06 2010-08-12 Egalet A/S Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA3039920A1 (en) 2016-10-10 2018-04-19 Rhodes Pharmaceuticals L.P. Pharmaceutical resinate compositions and methods of making and using thereof
WO2019074829A1 (en) 2017-10-09 2019-04-18 Rhodes Pharmaceuticals L.P. RESINATE-BASED PHARMACEUTICAL COMPOSITIONS, AND METHODS OF MAKING AND USING THEM
CN110420191A (zh) * 2019-09-06 2019-11-08 北京兴源联合医药科技有限公司 一种包含左甲状腺素钠的口腔崩解片

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) * 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) * 1960-11-29
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) * 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) * 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) * 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111201A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4207893A (en) * 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
GB2203039B (en) * 1987-03-02 1990-10-24 American Cyanamid Co Stable ophthalmic preparations containing acetazolamide
US4940465A (en) * 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) * 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US4915949A (en) * 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4824675A (en) * 1987-07-13 1989-04-25 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
IL103172A (en) * 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5262171A (en) * 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
US5413672A (en) * 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5817321A (en) * 1992-10-08 1998-10-06 Supratek Pharma, Inc. Biological agent compositions
EP0716595B1 (en) * 1993-08-31 1998-11-25 Alza Corporation Dispenser containing hydrophobic agent
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ATE216220T1 (de) * 1997-12-05 2002-05-15 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
CA2301042A1 (en) * 1998-06-11 1999-12-16 Em Industries, Inc. Micro-osmotic controlled drug delivery systems
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1126827A2 (en) * 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
EP1187604A4 (en) * 1999-05-28 2004-02-11 Jeffrey Berlant CONNECTIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS FAILURES
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US6946243B2 (en) * 2000-07-20 2005-09-20 Solvay Pharmaceuticals Gmbh Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
EP1370610B1 (en) * 2000-11-28 2008-09-10 Genzyme Corporation Polyalkylene glycol viscosity-enhancing polymeric formulations
WO2003004009A1 (en) * 2001-07-02 2003-01-16 Geneva Pharmaceuticals, Inc. Pharmaceutical composition
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003224794A1 (en) * 2002-03-29 2003-10-13 Alza Corporation Volume efficient controlled release dosage form
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement

Also Published As

Publication number Publication date
US20040091529A1 (en) 2004-05-13
AU2003280087A8 (en) 2004-01-19
AU2003280087A1 (en) 2004-01-19
WO2004002447A2 (en) 2004-01-08
PE20040103A1 (es) 2004-02-25
WO2004002447A3 (en) 2004-06-10
EP1517671A2 (en) 2005-03-30
CA2489688A1 (en) 2004-01-08
CN1678290A (zh) 2005-10-05
TW200500098A (en) 2005-01-01

Similar Documents

Publication Publication Date Title
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
AR030253A1 (es) Sistemas de suministro de drogas autoemulsionantes para drogas lipofilicas extremadamente insolubles en agua, una formulacion y el uso de una composicion para la fabricacion de un medicamento
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
AR004391A1 (es) Formulacion de liberacion controlada para farmacos basicos escasamente solubles.
HRP20060147B1 (hr) Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu
AR111572A2 (es) Formas farmacéuticas que contienen vardenafilo
NO20061859L (no) OROS Push Stick for kontrollert tilforsel av aktive midler
AR062167A1 (es) Sistema de administracion gastrorretentivo
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
MXPA05007643A (es) Metodo para producir una forma farmaceutica oral con desintegracion inmediata y liberacion de ingrediente activo.
MXPA02004235A (es) Dosificacion de farmacos a traves de la mucosa oral usando una solucion solida.
AR045076A1 (es) Composicion de pelicula que se disuelve oralmente, pelicula multicomponente que se disuelve oralmente, uso de la composicion de pelicula y de la pelicula que se disuelve oralmente para preparar un medicamento, forma de dosificacion oral y procedimiento para preparar la composicion de pelicula que se
AR033688A1 (es) Composicion parenteral reconstituible
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
AR022589A1 (es) UNA CÁPSULA QUE COMPRENDE UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL, UNA COMPOSICIoN FARMACÉUTICA ESPONTÁNEAMENTE DISPERSABLE PARA LA ADMINISTRACIoN ORAL Y EL USO PARA LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER
AR062647A1 (es) Formulaciones farmaceutica y metodos de uso
SG146638A1 (en) Pharmaceutical delivery system
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
BRPI0406858A (pt) Liberação controlada de agentes altamente solúveis
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR046036A1 (es) Composiciones de risedronato y metodos para su uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure